The Journal of Practical Medicine >
Analysis of risk factors for acute liver injury after cTACE in hepatocellular carcinoma patients
Received date: 2026-03-13
Online published: 2026-06-15
Objective To explore the risk factors associated with acute liver injury in patients with hepatocellular carcinoma (HCC) following hepatic artery chemoembolization (cTACE). Methods A retrospective analysis was conducted on the clinical data of 252 HCC patients who received cTACE treatment at the Affiliated Hospital of Xuzhou Medical University and Xuzhou Central Hospital from January 2024 to July 2025. The patients were divided into an acute liver injury group and a non-acute liver injury group based on whether acute liver injury occurred after surgery. Independent risk factors were screened through multiple logistic regression analysis. Results Multivariate analysis indicated that giant hepatocellular carcinoma, Child-Pugh B grade, combined cirrhosis, TACE frequency greater than 2 times, preoperative albumin (ALB) less than 30 g/L, an increase in the preoperative fibrosis factor 4 index (FIB-4), an increase in the preoperative neutrophil/lymphocyte ratio (NLR), an increase in the preoperative platelet count index (APRI), and a decrease in the postoperative liver volume (LV) were all independent risk factors for acute liver injury in HCC patients undergoing cTACE (all P < 0.05). ROC curve analysis demonstrated that the areas under the curve (AUC) for predicting acute liver injury after cTACE by preoperative FIB-4, NLR, APRI, and postoperative LV were 0.786, 0.704, 0.816, and 0.847, respectively; The sensitivities were 0.716, 0.672, 0.761, and 0.821, respectively; The specificities were 0.708, 0.701, 0.805, and 0.836, respectively. Conclusions The occurrence of acute liver injury after cTACE in HCC patients is influenced by factors including massive HCC, Child-Pugh class B, concurrent liver cirrhosis, more than 2 TACE sessions, preoperative ALB < 30 g/L, preoperative FIB-4, preoperative NLR, preoperative APRI, and postoperative LV.
Buqiang ZHUANG , Duntao Lü , Mingming JIANG , Meide WANG , Xichang ZHOU . Analysis of risk factors for acute liver injury after cTACE in hepatocellular carcinoma patients[J]. The Journal of Practical Medicine, 2026 , 42(11) : 2064 -2069 . DOI: 10.3969/j.issn.1006-5725.2026.11.022
| [1] | FENG F, ZHAO Y. Hepatocellular carcinoma: Prevention, diagnosis, and treatment[J]. Med Princ Pract, 2024, 33(5): 414-423. doi:10.1159/000539349 . |
| [2] | 沈未, 鲁迪, 徐骁. 肝癌肝移植适应证的科学演进[J]. 器官移植, 2025, 16(2): 202-207. doi: 10.12464/j.issn.1674-7445. 2025064 |
| [3] | BROWN A M, KASSAB I, MASSANI M, et al. TACE versus TARE for patients with hepatocellular carcinoma: Overall and individual patient level meta analysis[J]. Cancer Med, 2023, 12(3): 2590-2599. doi:10.1002/cam4.5125 . |
| [4] | 崔佳琪, 吴迪, 陈海艳, 等. TACE术后并发肝脓肿的临床诊治分析[J]. 中华肝脏外科手术学电子杂志, 2023, 12(6): 688-693. doi: 10.3877/cma.j.issn.2095-3232.2023.06.018 . |
| [5] | 张昀昊, 胡涛, 王钊, 等. 血清前白蛋白、总胆红素、凝血酶原活动度对原发性肝癌靶向药物联合经动脉插管化疗栓塞术治疗所致肝损伤预测价值分析[J]. 临床军医杂志, 2024, 52(7): 706-708. doi:10.16680/j.1671-3826.2024.07.12 . |
| [6] | 中华人民共和国国家卫生健康委员会医政司. 原发性肝癌诊疗指南(2024年版)[J]. 协和医学杂志, 2024, 15(3): 532-558. doi:10.12290/xhyxzz.2024-0304 . |
| [7] | 中国临床肿瘤学会肿瘤支持与康复治疗专业委员会, 中国抗癌协会癌症康复与姑息治疗专业委员会, 肿瘤药物相关性肝损伤诊疗指南工作组, 等. 肿瘤药物相关性肝损伤诊疗指南(2025年版)[J]. 国际肿瘤学杂志, 2025, 52(8): 470-483. doi: 10.3760/cma.j.cn371439-20250312-00082 . |
| [8] | 杨凯仑, 李智, 任起梦, 等. 肝动脉化疗栓塞术不同化疗方案治疗原发性肝癌的疗效及安全性[J]. 实用医学杂志, 2022, 38(5): 594-599. doi: 10.3969/j.issn.1006-5725.2022.05.014 . |
| [9] | 李榕, 李文利, 袁国盛, 等. 肝动脉灌注化疗术联合靶免对比经动脉插管化疗栓塞术联合靶免治疗中晚期肝癌患者术后引起肝损伤的研究[J]. 中华肝脏病杂志, 2023, 31(11): 1163-1168. doi:10.3760/cma.j.cn501113-20230827-00070 . |
| [10] | 周禄科, 杨洁, 刘林, 等. 92例老年肝癌患者TACE后肝功能代偿不全的危险因素分析[J]. 临床消化病杂志, 2022, 34(3): 189-193. doi:10.3870/lcxh.j.issn.1005-541X.2022.03.07 . |
| [11] | POSE E, JIMéNEZ C, ZACCHERINI G, et al. Simvastatin and rifaximin in decompensated cirrhosis: A randomized clinical trial[J]. JAMA, 2025, 333(10): 864. doi:10.1001/jama.2024. 27441 . |
| [12] | 卢双动, 王会哲, 王谦. 肝癌TACE术后急性肝功能恶化的危险因素及风险列线图模型的构建与验证[J]. 中西医结合肝病杂志, 2024, 34(10): 884-888. doi:10.3969/j.issn.1005-0264.2024.010.005 . |
| [13] | LI R, LIU J, YE F, et al. Microbial metabolism dysfunction induced by transarterial chemoembolization aggravates postprocedural liver injury in HCC[J]. J Hepatol, 2026, 84(4): 808-822. doi:10.1016/j.jhep.2025.10.008 . |
| [14] | YOU R, LENG B, WANG C, et al. Comparison of liver injury and inflammatory response following conventional and drug-eluting bead transcatheter chemoembolization in hepatocellular carcinoma[J]. Discov Oncol, 2025, 16(1): 504. doi:10.1007/s12672-025-02286-9 . |
| [15] | EKMEN M O, UZMAN M. The relationship between mean platelet volume and neutrophil–lymphocyte ratio and liver fibrosis in patients with chronic hepatitis B[J]. Medicina, 2023, 59(7): 1287. doi:10.3390/medicina59071287 . |
| [16] | 吴玲红, 周敏, 卢瑶, 等. 中性粒细胞/淋巴细胞比值及其变化值对肝细胞癌介入术后急性肝功能恶化风险的预测价值[J]. 实用医学杂志, 2023, 39(6): 713-718. doi:10.3969/j.issn. 1006-5725.2023.06.010 . |
| [17] | 王会哲, 卢双动, 王谦, 等. 肝癌介入术后急性肝功能恶化的风险列线图模型的构建与验证[J]. 肝脏, 2024, 29(6): 681-686. doi:10.3969/j.issn.1008-1704.2024.06.016 . |
| [18] | 任艳, 徐曼曼, 孔明, 等. 瞬时弹性成像技术和血清无创预测模型对慢性药物性肝损伤患者肝纤维化的预测价值[J]. 肝脏, 2024, 29(3): 269-272. doi: 10.3969/j.issn.1008-1704.2024. 03.006 . |
| [19] | SANTOL J, KIM S, GREGORY L A, et al. An APRI+ALBI-based multivariable model as a preoperative predictor for posthepatectomy liver failure[J]. Ann Surg, 2025, 281(5): 861-871. doi:10.1097/sla.0000000000006127 . |
| [20] | 王燕慧, 张秀真, 刘芳, 等. 肝转移瘤患者TACE术后肝脏体积变化对肝功能及预后的影响[J]. 实用癌症杂志, 2024, 39(1): 141-144. doi: 10.3969/j.issn.1001-5930.2024.01.035 . |
/
| 〈 |
|
〉 |